文献速递血栓与止血

口服抗凝药治疗静脉血栓栓塞症住院出血风险比较

Risk of hospitalised bleeding in comparisons of oral anticoagulant options for the primary treatment of venous thromboembolism.
PubMed 文献 · Br J Haematol · 2019-03-28

在2011至2016年MarketScan数据库中,83 985例未接受过抗凝治疗的静脉血栓栓塞症患者被纳入分析,比较阿哌沙班、利伐沙班与华法林起始治疗后180天内住院出血事件。多变量校正Cox模型显示,阿哌沙班住院出血率低于利伐沙班和华法林,利伐沙班与华法林总体相似。

要点

  • 阿哌沙班住院出血率低于利伐沙班,风险比0.58(95%CI 0.41-0.80)。
  • 阿哌沙班住院出血率低于华法林,风险比0.68(95%CI 0.50-0.92)。
  • 利伐沙班与华法林住院出血率总体相似,风险比0.98(95%CI 0.68-1.11)。

核心结论

  • 在大型真实世界静脉血栓栓塞症人群中,阿哌沙班住院出血风险低于利伐沙班和华法林,利伐沙班与华法林总体相似。

研究设计与样本

  • 基于MarketScan数据库2011至2016年数据的队列研究,纳入83 985例未接受过抗凝治疗的静脉血栓栓塞症患者,每种口服抗凝药比较时新使用者与至多5例其他口服抗凝药起始者匹配。

主要发现

  • 最终分析纳入83 985例静脉血栓栓塞症患者,共发生1944例住院出血事件。
  • 多变量校正Cox回归模型中,阿哌沙班新使用者住院出血率低于利伐沙班新使用者,风险比0.58(95%CI 0.41-0.80)。
  • 阿哌沙班新使用者住院出血率低于华法林新使用者,风险比0.68(95%CI 0.50-0.92)。
  • 利伐沙班新使用者与华法林新使用者住院出血率总体相似,风险比0.98(95%CI 0.68-1.11),但在年轻个体中利伐沙班可能与较低出血风险相关。

关键数值与推荐

  • 阿哌沙班 vs 利伐沙班住院出血风险比0.58(95%CI 0.41-0.80)。
  • 阿哌沙班 vs 华法林住院出血风险比0.68(95%CI 0.50-0.92)。
  • 利伐沙班 vs 华法林住院出血风险比0.98(95%CI 0.68-1.11)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Understanding of the comparative bleeding risks of oral anticoagulant (OAC) therapies for the primary treatment of venous thromboembolism (VTE) is limited. Therefore, among anticoagulant-naïve VTE patients, we conducted comparisons of apixaban, rivaroxaban and warfarin on the rate of hospitalised bleeding within 180 days of OAC initation. MarketScan databases for the time-period from 2011 to 2016 were used and, for each OAC comparison, new users were matched with up to five initiators of a different OAC. The final analysis included 83 985 VTE patients, who experienced 1944 hospitalised bleeding events. In multivariable-adjusted Cox regression models, rate of hospitalised bleeding was lower among new users of apixaban when compared to new users of rivaroxaban [hazard ratio (95% confidence interval) 0·58 (0·41-0·80)] or warfarin [0·68 (0·50-0·92)]. Overall, the hospitalised bleeding rate was similar when comparing new users of rivaroxaban to new users of warfarin [0·98 (0·68-1·11)], though there was some suggestion that rivaroxaban was associated with lower bleeding risk among younger individuals. Findings from this large real-world population concur with results from the randomised trial which found lower bleeding risk with apixaban versus warfarin and, for the first time, reveal a lower risk of bleeding in a comparison of apixaban versus rivaroxaban.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Lutsey PL, Zakai NA, MacLehose RF, et al. Risk of hospitalised bleeding in comparisons of oral anticoagulant options for the primary treatment of venous thromboembolism. Br J Haematol. 2019. PMID: 30919942. doi:10.1111/bjh.15857

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。